Bio-Techne Corp at JPMorgan Healthcare Conference Transcript

Jan 11, 2023 / 04:15PM GMT
Rachel Marie Vatnsdal Olson - JPMorgan Chase & Co, Research Division - Analyst

Hi, everyone. This is Rachel Vatnsdal from the Life Science Tools and Diagnostics team here at JPMorgan. Today, I am joined by Jim Hippel from the Bio-Techne team. This will be a standard 40-minute presentation, 20 minutes of slides, followed by 20 minutes of Q&A. For those of you listening online via webcast, feel free to submit your questions via the Q&A function. And for those of you in the room, we will have mic runners. So if you have a question, feel free to raise your hand.

With that, Jim?

James T. Hippel - Bio-Techne Corporation - Executive VP of Finance & CFO

Thank you. Good morning, everyone. Thanks for joining us this morning, and thank you to JPMorgan for having us for the conference. And unfortunately, Chuck fell ill, our CEO, Chuck Kummeth fell ill yesterday and was still recovering this morning. So I got the call to take his place. And in doing so, he reminded me that 9 years ago was the first time ever in the history of our 40-year company that

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot